Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid by Antiga, E et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Antiga E; Quaglino P; Volpi W; Pierini I; Del Bianco E; Bianchi B; Novelli
M; Savoia P; Bernengo M.G.; Fabbri P; Caproni M.. Regulatory T cells in
skin lesions and blood of patients with bullous pemphigoid. JOURNAL OF
THE EUROPEAN ACADEMY OF DERMATOLOGY AND
VENEREOLOGY. 28 (2) pp: 222-230.
DOI: 10.1111/jdv.12091
The publisher's version is available at:
http://doi.wiley.com/10.1111/jdv.12091
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/142764
Regulatory T cells in skin lesions and blood of 
patients with bullous pemphigoid 
Antiga E, Quaglino P, Volpi W, Pierini I, Del Bianco E, Bianchi B, Novelli M, 
Savoia P, Bernengo MG, Fabbri P, Caproni M 
Abstract 
Background 
Although regulatory T cells (Tregs) are affected in several autoimmune skin diseases, only two 
studies have been performed in patients with bullous pemphigoid (BP) with contrasting results. 
Objective 
To characterize Tregs and to determine the serum levels of regulatory cytokines in patients with BP. 
Methods 
In BP lesional skin, immunohistochemistry and confocal microscopy were performed for CD4+, 
CD25+, forkhead/winged helix transcription factor (FOXP3)+, transforming growth factor (TGF)-β+ 
and interleukin (IL)-10+ cells. In addition, the number of CD4+CD25++FOXP3+ Tregs in peripheral 
blood was assessed by flow cytometry, and the levels of TGF-β and IL-10 were determined in 
serum samples by enzyme-linked immunosorbent assay before and after steroid therapy. Controls 
included patients with psoriasis, atopic dermatitis (AD) and healthy donors. 
Results 
The frequency of FOXP3+ cells was significantly reduced in skin lesions from patients with BP 
(P < 0.001) compared with psoriasis and AD. Moreover, the number of IL-10+ cells was lower in 
BP than in psoriasis (P < 0.001) and AD (P = 0.002), while no differences were observed in the 
number of TGF-β+ cells. CD4+CD25++FOXP3+ Treg in the peripheral blood of patients with BP was 
significantly reduced compared with healthy controls (P < 0.001), and augmented significantly after 
steroid therapy (P = 0.001). Finally, TGF-β and IL-10 serum levels were similar in patients with BP 
compared with healthy controls. However, after therapy, BP patients showed significantly higher 
IL-10 serum levels than before therapy (P = 0.01). 
Conclusions 
These data suggest that the depletion of Tregs and of IL-10 in patients with BP may be an important 
factor in the pathogenesis of the disease. 
Introduction 
Regulatory T cells (Tregs) represent a subset of immune effector cells, firstly described by 
Sakaguchi et al.,[1] which play a central role in immune homeostasis by regulating the maintenance 
of self-tolerance and are therefore essential for the control of immune responses.[2-4] 
Currently, distinct subsets of Tregs have been described,[2] subdivided on the basis of different 
expression of cell surface markers, production of cytokines and mechanism of action.[5] Naturally 
occurring thymic-derived CD4+CD25+ Tregs (nTregs) represent 1–10% of total CD4+ T cells in 
thymus, peripheral blood and lymphoid tissues, and acquire their regulatory capacity during normal 
thymopoiesis. Phenotypically, nTregs are characterized by the bright expression of CD25 and by 
the constitutive expression of specific markers, such as the transcription factor forkhead box P3 
(FOXP3),[4] the glucocorticoid-induced tumour-necrosis factor receptor-related protein and the 
cytotoxic T-lymphocyte associated antigen 4. Another group of CD4+CD25+ Tregs is represented 
by the ‘antigen induced or adaptive’ Tregs (aTregs). The suppressive function of these induced 
Tregs is mediated by the production of the suppressive cytokines interleukin (IL)-10 and 
transforming growth factor (TGF)-β. 
Recent literature proposed that a lack of Tregs number or a defect in function could potentially lead 
to loss of tolerance and thus to the development of autoimmunity. Indeed, numerous autoimmune 
and immune-mediated diseases (including gastritis, thyroiditis, type 1 diabetes, myastenia gravis, 
rheumatoid arthritis and multiple sclerosis) have been shown to present significant depletion in the 
number and/or function impairment of Tregs.[2-4, 6, 7] A significant down-modulation of Tregs 
was found also in different immune-mediated dermatoses, such as psoriasis, scleroderma, 
dermatomyositis, lupus erythematosus and graft-versus-host disease.[8-12] 
To date, only a few studies focused on Tregs in autoimmune bullous skin diseases, a group 
including different clinical-pathological entities characterized by the development of autoimmunity 
against structural components maintaining cell-cell (pemphigus group) and cell-matrix [bullous 
pemphigoid (BP) group] adhesion. In particular, BP, the most common autoimmune blistering 
disease, is characterized by the development of auto-antibodies directed against components of the 
hemidesmosome adhesion complex, the BP230 and collagen XVII/BP180 proteins. Although the 
underlying mechanisms involved in triggering the autoimmune response in BP are not well-
understood, BP is now considered a T-cell dependent autoimmune disease with the presence of 
CD4+ autoreactive T cells that recognize the ectodomain of BP180.[13-15] The pathogenesis of the 
disease involves also other factors, including complement activation, mast cell degranulation, 
accumulation of inflammatory cells (eosinophils, neutrophils) and the release of proteases.[13, 16-
18] 
Although Tregs pathway seems to be impaired in pemphigus vulgaris,[19-22] contrasting results are 
reported for BP. In fact, while Rensing-Ehl et al. did not find differences between BP patients and 
healthy controls,[23] more recently a study by Arakawa and co-workers[24] and a study from our 
research group[25] demonstrated a reduction in Tregs numbers in the skin and in the blood of BP 
patients respectively. 
In this study, to confirm our previous results and to analyse further the role of Tregs in the 
pathogenesis of BP, the expression and distribution of both naturally-occurring FOXP3+ Tregs and 
‘antigen-induced’ IL-10 and TGF-β producing Tregs, have been investigated using 
immunohistochemistry, confocal microscopy, flow-cytometry and ELISA both in the lesional skin 
and in the blood of patients with BP. 
Materials and methods 
Patients 
A total of 21 patients with BP (9 M, 12 F; median age 68 years, range 39–84) were included into the 
study. The diagnosis of BP was made on the basis of a typical clinical presentation of classic BP 
with diffuse blistering of the skin, subepidermal blistering with granulocytic infiltrate at the 
histopathology, linear immunoglobulin G (IgG) and complement three deposits along the basement 
membrane zone at the direct immunofluorescence examination, linear IgG deposits at the blister 
roof of sodium chloride split human skin at the indirect immunofluorescence, and presence of 
circulating anti-BP180 antibodies by ELISA. 
Skin biopsy specimens and blood samples from patients with psoriasis (n = 10, 4 M, 6 F; median 
age 44 years, range 26–61) and atopic dermatitis (AD) (n = 10; 5 M, 5 F, median age 38 years, 
range 22–59) were used as controls, along with skin and blood samples from 30 age- and gender-
matched healthy controls (HC). The patients and controls were recruited from two Italian 
Dermatologic Clinics (Florence and Turin) belonging to the Italian Group for Cutaneous 
Immunopathology. 
All patients and controls underwent a skin biopsy and a peripheral blood test during the first visit 
and before any topical and/or systemic treatment was started. Furthermore, a blood sample was 
collected from 11 BP patients at the end of consolidation phase as defined by Murrell et al.[26] 
Table 1 shows the therapy regimens and the time needed to achieve the end of consolidation phase 
for each BP patient included into the study. 
Table 1. Therapy regimens and time to achieve end of consolidation phase for each patient 
Patient 
no Therapy (higher dosage) 
Time to achieve end of consolidation 
phase 
1 Prednisone 0.5 mg/Kg/day 3 months 
2 Topical clobetasol 20 g/day 2 months 
3 Prednisone 0.75 mg/Kg/day 4 months 
4 Prednisone 0.5 mg/Kg/day 3 months 
5 Prednisone 0.5 mg/Kg/day 2 months 
6 Prednisone 0.75 mg/Kg/day 3 months 
7 Prednisone 0.5 mg/Kg/day + azathioprine 200 mg/day 5 months 
8 Topical clobetasol 25 g/day 45 days 
9 Prednisone 1 mg/Kg/day 3 months 
10 Prednisone 0.5 mg/Kg/day + azathioprine 200 mg/day 3 months 
11 Prednisone 0.5 mg/Kg/day 45 days 
12 Prednisone 0.5 mg/Kg/day 4 months 
13 Prednisone 1 mg/Kg/day 5 months 
14 Prednisone 0.75 mg/Kg/day 3 months 
15 Topical clobetasol 20 g/day 3 months 
16 Prednisone 0.5 mg/Kg/day + azathioprine 200 mg/day 4 months 
17 Prednisone 1 mg/Kg/day 3 months 
18 Topical clobetasol 30 g/day 3 months 
19 Topical clobetasol 25 g/day 2 months 
20 Prednisone 0.5 mg/Kg/day 45 days 
21 Prednisone 1 mg/Kg/day 2 months 
The trial was approved by the medical ethical committee of each Hospital and was conducted 
according to the Declaration of Helsinki. All the patients and controls provided written informed 
consent to participate to the study. 
Immunohistochemistry 
The expression of different Tregs markers was analysed in serial sections of lesional skin biopsy 
specimens of 15 BP patients, 10 psoriasis patients, 10 AD patients, as well as in healthy skin of 
eight HC using single immunohistochemical staining as described previously.[27] 
Skin specimens, that had been immediately frozen at −80 °C in liquid nitrogen, were cut into 5–μm 
thick sections and stained immunohistochemically. The monoclonal antibodies included those to 
CD4 (1 : 50; DAKO, Copenhagen, Denmark), CD25 (1 : 10; DAKO), FOXP3 (1 : 40; Abcam Ltd., 
Cambridge, UK), TGF-β (1 : 2000; R&D Systems, Minneapolis, MN, USA) and IL-10 (1 : 50; 
DAKO). Before staining, frozen sections were air-dried and fixed in acetone (5 min). 
Immunolabeling was performed with the alkaline phosphatase/antialkaline phosphatase complexes 
(1 : 30 dilution, 30 min; DAKO). FOXP3 peptide ab14151 (0.125 mg/mL; Abcam) was used as a 
control to block anti-FOXP3 binding. 
Two independent ‘blind’ observers evaluated the slides. For quantitative analysis, the stained cells 
were counted in three consecutive microscopic fields (400 × ). Furthermore, for each patient, 
FOXP3+/CD4+, TGF-β+/CD4+ and IL-10+/CD4+ cell ratios were calculated by counting the absolute 
number of positively stained cells in serial sections from the same skin biopsy specimen. 
Confocal microscopy 
About 10-μm serial sections of fresh frozen skin biopsies from eight patients with BP, five with 
psoriasis, five with AD and five HC were fixed with ice cold acetone then blocked with 0.25% 
casein in Tris-buffered saline (TBS; 0.88% NaCl, ThermoFisher, 0.24% tris(hydroxymethyl) 
aminomethane, (VWR International) and distilled water). Primary antibodies against human CD4 
(mouse IgG2b, OKT4, 1 : 50, BioLegend, San Diego, CA, USA) and FOXP3 (mouse IgG1, 206D, 
1 : 50, BioLegend) were prepared in TBS containing 1% FCS and incubated on sections for 1 h at 
room temperature. Secondary antibodies against mouse isotypes IgG2a DyLight 488 (poly24092, 
BioLegend) and IgG2b AlexaFluor 555 (Molecular Probes, Grand Island, NY, USA) at 1 : 200 each 
were prepared and incubated on sections for 1 h Sections were visualized with Nikon C2 confocal 
microscope (Nikon, Tokyo, Japan). 
Flow cytometric analysis 
The flow cytometric analysis was performed at a single site (Turin). Peripheral blood lymphocyte 
samples from 21 BP patients before therapy and 11 BP patients (number 1, 3, 4, 5, 6, 7, 8, 12, 13, 
17, 19; see Table 1) after therapy were evaluated according to their immunofluorescence reactivity, 
using FACSCalibur or FACSCanto™ II cytometer and analysed with CellQuest or FACSDiva 
software (Becton Dickinson, San Jose, CA, USA). Surface markers on blood were performed by 
four or six-colour immunofluorescence analyses, using simultaneously antibodies conjugated to 
FITC, PE, PerCP or PerCP Cy5.5, Pe-Cy7, allophycocyanin (APC) and APC-H7. At least 10 000 
lymphocytes were collected for each antibody combination. Lymphocyte purity was verified by the 
standard forward and sideways scattering parameters, by means of a CD45 gating analysis. A wide 
panel of mAbs directed against T-cell antigens was routinely tested to screen patients' phenotypes. 
The following mAbs were analysed for this study: anti-CD4 PerCP or Pe-Cy7 (clone SK3, mouse 
IgG1) from (BD Biosciences, San Jose, CA, USA) anti-CD25 PE, or APC (clone CD25-3G10, 
mouse IgG1) from Caltag, Burlingame CA, USA). The CD4+CD25+ population can be divided into 
two different levels of expression, i.e. cells that express a low CD25 level (defined CD4+CD25low) 
and cells with a higher CD25 level (defined CD4+CD25bright) that appear to have a tail to the right of 
the major population containing both CD4+CD25low and CD4+CD25– cells. FOXP3 cytometric 
expression was analysed using mononuclear cells purified from peripheral blood using Lymphoprep 
(1.077 g/mL; Axis-Shield Poc As, Oslo, Norway) density gradient centrifugation. Firstly, the cells 
were incubated with surface antibodies, anti-CD4 PerCP or PE-Cy7 and anti-CD25 APC for 10 min 
at room temperature. They were then stained with anti-FOXP3 PE (clone PCH101, rat IgG2a; 
eBiosciences, San Diego, CA, USA), according to the manufacturer's protocol, using fixation and 
permeabilization buffers from the same provider. Evaluation of Tregs subpopulations by flow 
cytometry was determined as the percentage expression of CD25brightFOXP3+ within the CD3+CD4+ 
compartment. Blood samples of 10 patients with psoriasis, 10 with AD and 30 HC were 
investigated as controls; data of the patients with psoriasis and AD were retrieved from our previous 
study, where the same methods were used.[10] 
Enzyme-linked immunosorbent assay 
As for flow cytometric assay, even the ELISA was performed at a single site (Florence). Blood 
samples from 21 BP patients were collected at the diagnosis and after the resolution of the disease 
and were centrifuged for 20 min at 10000 g (5417R microcentrifuge; Eppendorf, Hamburg, 
Germany). Then, serum samples were subdivided into small aliquots to be stored at −80°C until 
tested for cytokine levels. Solid phase ELISA kits (R&D Systems, Minneapolis, MN, USA) were 
used to determine TGF-β1 and IL-10 serum levels, according to the manufacturers' instructions. 
Samples and standards were analysed in duplicates and only variation coefficients <15% were 
accepted. As control, serum samples of 10 HC were analysed. 
Statistical analysis 
The results are presented as medians [25th–75th percentile]. The Mann–Whitney U-test was used to 
compare the number of Tregs in peripheral blood of patients and healthy controls and the results of 
the immunohistochemical and confocal microscopy analysis. Both the Kruskal–Wallis with Dunn 
post hoc test and the Student's t-test were used to compare the data from the ELISA analysis, giving 
similar results. The results of flow cytometric analysis and ELISA in BP patients before and after 
treatment were paired and analysed using Wilcoxon signed rank test. The correlation between the 
percentages of circulating Tregs with IL-10 serum levels in BP patients after treatment was 








CD4+, CD25+ and FOXP3+ nTregs in the skin of patients with BP (Table 2) 
CD4+ and CD25+ cells were located in the superficial dermis in patients with BP (Fig. 1). 
Table 2. Quantitative analysis on the numbers of positive cells for field (400X) in skin lesions of 
bullous pemphigoid patients and controls as assessed by immunohistochemistry and confocal 
microscopy 
  BP HC Psoriasis AD 
1. Positive-cell counts are expressed as medians [25th–75th percentile]. 
2. BP, bullous pemphigoid; HC, healthy controls; AD, atopic dermatitis. 
CD4+ cells 61 [53.5–67.5] 5 [4–6.5] 71.5 [57.3–77.3] 61.5 [54–72.7] 
CD25+ cells 17 [5.5–25.5] 2 [1–3] 35 [26.7–42.7] 33 [27.5–42.7] 
FOXP3+ cells 1 [0–2] 1 [0–1.2] 27.5 [20–32.5] 22.5 [16.7–26.5] 
% FOXP3+/CD4+ 1.9 [0–3.1] 18.7 [0–25] 33.7 [31.1–39.5] 37.6 [31.3–41.4] 
CD4+FOXP3+ cells 0.5 [0–2] 0 [0–1] 22 [17.5–28] 19.5 [16–25] 
TGF-β+ cells 20 [15.5–27] 2.5 [1.7–3] 22.5 [12.5–27.7] 19.5 [12.5–23.7] 
% TGF-β+/CD4+ 42.2 [22.9–51.1] 38.7 [32.3–48.7] 34.2 [19.3–39] 35.6 [21.4–41.6] 
IL-10+ cells 1 [0–2.5] 1 [1–1.2] 16.5 [9.2–22] 5.5 [4–7.7] 














Figure 1.  
 
Immunohistochemical staining for CD4, CD25, FOXP3, TGF-β and IL-10, as well as double staining of CD4+FOXP3+ 
cells assessed by confocal microscopy, in skin biopsy specimens from patients with bullous pemphigoid. Positive cells 
are mainly distributed within the superficial dermis. 
The level of CD4+ cell infiltration was similar in patients with BP, psoriasis and AD. HC showed 
significantly lower numbers of CD4+ infiltrating cells than BP and control diseases (HC vs. BP, 
psoriasis and AD: P < 0.001) (Fig. 1). In contrast, the frequency of CD25+ cells was significantly 
lower in BP skin lesions compared with psoriasis (P = 0.008) and AD (P = 0.01), and higher 








Figure 2.  
 
Numbers of CD4+, CD25+, FOXP3+, TGF-β+ and IL-10+ cells as well as FOXP3/CD4, TGF-β/CD4 and IL-10/CD4 cell 
ratios in the inflammatory infiltrate of skin biopsy specimens from patients with bullous pemphigoid, healthy controls 
or patients with psoriasis and atopic dermatitis. BP, bullous pemphigoid; HC, healthy controls; PSO, psoriasis; AD, 
atopic dermatitis; *P < 0.05. 
In BP inflammatory infiltrate, few FOXP3+ cells were identified within the superficial dermis 
(Fig. 1). In contrast, patients with psoriasis and AD revealed a significantly higher number of 
FOXP3+ cells in the infiltrate (BP vs. psoriasis: P < 0.001; BP vs. AD: P = 0.001) (Fig. 2). No 
differences could be found in the absolute number of FOXP3-expressing cells between BP patients 
and HC (Fig. 2). 
The binding of FOXP3 antibody could be blocked by preincubating the antibody with specific 
FOXP3 peptide in skin specimens. For control purposes, an isotype-matched control antibody was 
used and consistently yielded negative results. The frequency of FOXP3+ cells, expressed as the 
percentage of CD4+ cells, was found to be significantly lower in BP specimens compared with HC 
(P = 0.009), psoriasis (P < 0.001) and AD (P < 0.001) (Fig. 2). 
Finally, the number of CD4+FOXP3+ double stained cells investigated by confocal microscopy 
(Fig. 1) was significantly lower in BP patients and in HC than in patients with psoriasis and AD (BP 
vs. psoriasis: P < 0.001; BP vs. AD: P = 0.001). 
Quantification of TGF-β+ and IL-10+ cells in the skin of patients with BP (Table 2) 
Several TGF-β+ cells preferentially located in the superficial dermis (Fig. 1) were detected in BP, 
without statistical differences compared with psoriasis and AD (Fig. 2). In contrast, HC showed a 
reduced number of TGF-β+ if compared with BP (P < 0.001), psoriasis (P < 0.001) and AD 
(P < 0.001). Finally, TGF-β+/CD4+ cell ratio was similar in BP, HC, psoriasis and AD skin 
specimens. 
Only few IL-10+ cells were found in the superficial dermis of BP skin lesions (Fig. 1). Their 
number was similar to that found in HC, but significantly lower than in patients with psoriasis 
(P < 0.001) or AD (P = 0.02) (Fig. 2). Furthermore, IL-10+/CD4+ cell ratio was lower in BP skin 
lesions than in HC (P < 0.001), in AD (P = 0.003) and in psoriasis (P < 0.001). 
Peripheral blood Tregs quantification (Figure 3) 
The presence of CD25brightFOXP3+ within the CD4+ circulating compartment was analysed in BP 
and compared with HC, psoriasis and AD patients (Fig. 3a). The dot plot of a representative BP 
patient is reported in Fig. 3b. 
 
Figure 3.  
 
(a) Percentages of the CD25brightFOXP3+ subpopulation within the CD4+ cell subset in bullous pemphigoid patients 
(before and after therapy) compared with healthy controls and patients with psoriasis and atopic dermatitis. Each dot 
represents a patient; horizontal bars indicate median values. HC, healthy controls; BP-pre, bullous pemphigoid before 
therapy; BP-post, bullous pemphigoid after therapy; PSO, psoriasis; AD, atopic dermatitis; *P < 0.05. (b) 
Representative dot plot from a BP patient. The gate A shows CD25brightFOXP3+ subpopulation within the CD4+ cell 
subset. 
The frequency of CD25brightFOXP3+ within the CD4+ subset was significantly reduced in BP 
patients (median [25th–75th percentile]: 1.5%[1%–2.9%]) with respect to HC (median [25th–75th 
percentile]: 3.5%[2.9%–4%]; P < 0.001). The percentages of the CD25brightFOXP3+ subset in BP 
patients were also slightly lower than those of patients with both psoriasis and AD (median: 2.5% 
and 2.6% respectively), even if this difference was not significant (P = 0.07). 
The analysis of the circulating Tregs kinetics after treatment was available only in 11 patients. 
Interestingly, in these cases, the resolution of the skin lesions was associated with a parallel increase 
in the percentages of the CD25brightFOXP3+ cell subset (median [25th–75th percentile]: 3.4%[2.5–
4]; P = 0.001 with respect to baseline) up to HC values. 
TGF-ß and IL-10 concentrations in sera of BP patients before and after therapy 
To assess the concentrations of the regulatory cytokines TGF-β and IL-10, serum samples were 
investigated both in patients with BP and in HC. TGF-β concentrations were similar both in BP 
patients before treatment (median [25th–75th percentile]: 40.4 ng/mL [31.1–44.4]) and in HC 
(median [25th–75th percentile]: 35.5 ng/mL [33.7–45.3]). Moreover, TGF-β serum levels were not 
affected by therapy, and remained almost unchanged in treated patients after the resolution of the 
disease (median [25th–75th percentile]: 41.1 ng/mL [33.6–44.9]) (Fig. 4). 
 
Figure 4.  
 
Serum levels of the regulatory cytokines TGF-β and IL-10 in patients with bullous pemphigoid before and after therapy 
and in healthy controls. BP-pre, bullous pemphigoid before therapy; BP-post, bullous pemphigoid after therapy; HC, 
healthy controls; *P < 0.05. 
No significant differences in IL-10 concentrations were found between patients with BP before 
treatment (median [25th–75th percentile]: 8.9 pg/mL [4.3–15.7]) and HC (median [25th–75th 
percentile]: 15.2 pg/mL [14.4–17.5]). However, after therapy and thus after the resolution of the 
disease, BP patients showed significantly higher IL-10 serum levels than before therapy (median 
[25th–75th percentile]: 24.5 pg/mL [17.7–31.2]; P = 0.01) (Fig. 4). Interestingly, in treated patients, 
IL-10 serum levels showed a statistically significant correlation with the percentage of 
CD4+CD25brightFOXP3+ cells (P = 0.02). 
Discussion 
This study was designed to characterize the expression of both naturally-occurring and antigen-
induced Tregs in skin biopsies and blood samples from patients with BP, to evaluate their potential 
role in the pathogenesis of the disease. Our main finding was the demonstration of a significant 
reduction in Tregs in patients with BP compared with HC. 
Interestingly, our data showed that the decreased frequency of FOXP3+ Tregs was simultaneously 
present both in the skin and peripheral blood of patients with BP. According to a recent study by 
our research group,[25] this finding suggests that the reduction in Tregs observed in the blood was 
not the result of a preferential homing of these cells into the skin, or vice versa, but rather it reflects 
their real downregulation, and therefore, their potential impaired suppressive function that could 
play a role in the pathogenesis of the disease. 
Our results are in contrast with those by Rensing-Ehl et al.,[23] who did not find differences in the 
number of circulating Tregs between BP patients and HC. In their study, however, the analysis of 
circulating Tregs was made only the basis of the CD25bright expression, while no specific data on 
FOXP3+ cells in BP and HC were shown. Therefore, in that article, CD4+CD25bright cells could 
probably represent not only Tregs but also FOXP3− activated T cells, that are increased in BP. 
Moreover, Rensing-Ehl et al. found FOXP3+ Tregs also in the lesional skin of patients with BP[23]; 
however, they did not perform any cell count or statistical analysis, and did not calculate the 
FOXP3+/CD4+ ratio. The latter, rather than the absolute number of Tregs, is considered an 
important parameter in the evaluation of Tregs immunosuppressive activity, as Tregs/T effector cell 
ratios are decreased in patients with autoimmune and inflammatory diseases.[10, 11, 28] 
Accordingly, very recently Arakawa and coworkers found a reduced FOXP3+/CD4+ ratio in lesional 
skin of BP patients than in patients with pemphigus.[24] 
Interestingly, after a steroid course and thus after the end of consolidation phase of BP, we detected 
an increase in the number of circulating CD25brightFOXP3+ cells up to the values found in HC. This 
finding is in agreement with previous data from the literature, showing that immunosuppressive 
therapy either with oral steroids or with other immunosuppressant drugs is able to increase the pool 
of circulating Tregs.[29, 30] Although we tested only 11 patients after therapy and thus our results 
need further confirmation, the activity on Tregs could potentially be considered one of the curative 
effects of steroids in patients with BP. 
In this study, we also investigated TGF-β and IL-10, regulatory cytokines involved in Tregs 
suppressive function and particularly expressed by aTregs. Interestingly, while no differences were 
found in TGF-β+/CD4+ T cell ratio in BP patients and controls, the percentages of IL-10+ cells 
among CD4+ cells were significantly reduced in skin lesion of BP, suggesting a local deficiency of 
such cells, that could lead to a defective regulatory function. 
In contrast, we did not find any significant differences in the serum levels of both TGF-β and IL-10 
between patients with BP and HC. In agreement with our data, several studies from the literature 
demonstrated that, while IL-10 seems to be elevated in the blister fluid of patients with BP, its 
serum concentration overlaps that of healthy subjects.[31-33] 
However, after the resolution of the disease, BP patients showed higher IL-10 serum levels than 
before treatment. These findings might imply a relative lack of IL-10 in BP patients, where the 
levels of this cytokine, overlapping those of HC, could not be able to ensure an adequate 
immunoregulation in a state of enhanced reactivity such as BP. After steroid therapy which, as 
discussed above, is able to enhance Tregs numbers and function, IL-10 concentrations augmented 
consequently and reached levels that could be able to balance the autoimmune response present in 
BP patients. Accordingly, Teraki et al. demonstrated that corticosteroids may control inflammatory 
responses in BP by promoting expansion of IL-10-producing cells.[34] Interestingly, we also found 
a positive correlation between IL-10 serum levels and circulating Treg percentages in BP patients 
after treatment, suggesting that they are strictly related. 
IL-10 is a potent antiinflammatory cytokine that is able to suppress production of both type 1 and 
type 2 cytokines.[35] A number of studies have shown beneficial effects of IL-10 in different 
models of cell-mediated autoimmunity,[36, 37] including a model of BP.[38] Moreover, IL-10 is 
able to potentiate the IL-4-induced synthesis of IgG4,[39] a IgG subclass that is less pathogenic 
than IgG1 in patients with BP, as it is not capable of fixing complement.[40] Thus, taken as a 
whole, these data suggest that IL-10 could represent a therapeutic approach for the management of 
BP.[34] 
Our study, however, has some limitations, including the fact that FOXP3, although still considered 
the most specific marker for Tregs, can be transiently expressed on activated T cells. Further studies 
including functional assays and the use of other markers for Tregs, such as CD127low and 
CD39high,[41] would augment the specificity of the results. 
To conclude, despite such limitations, our findings suggested a reduction in both skin-homing and 
circulating FOXP3+ Tregs in patients with BP, together with a downregulation of the IL-10 
pathway. The resolution of the disease after a course with systemic corticosteroids was paralleled 
by an increase in circulating Tregs and of IL-10 serum levels, suggesting a possible alternative way 
of action of these drugs other than affecting T effector cells. 
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